Advertisement

Topics

FDA approves companion diagnostic test to simultaneously screen for multiple NSCLC therapies

04:08 EDT 23 Jun 2017 | Medical Business Review

The US Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific for the first next-generation sequencing (NGS)-based test that simultaneously screens tumor samples for biomarkers associated with three FDA-approved therapies for non-small cell lung cancer (NSCLC).

Original Article: FDA approves companion diagnostic test to simultaneously screen for multiple NSCLC therapies

NEXT ARTICLE

More From BioPortfolio on "FDA approves companion diagnostic test to simultaneously screen for multiple NSCLC therapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...